MDT · CIK 1613103
What Medtronic plc told the SEC could break it.
Medtronic's biggest flag is trade policy: it estimates a net tariff impact of $200 million to $350 million in fiscal 2026 from U.S., China and other tariffs, with the range hinging on whether current rates persist or revert to far higher levels after a 90-day pause, and with most landing in the back half of the year. That exposure runs through a global manufacturing base spread across the U.S., Puerto Rico, Mexico, China, Ireland and elsewhere, where certain components, raw materials and services come from sole suppliers it cannot quickly replace given stringent FDA manufacturing requirements. Demand and pricing are also shaped by healthcare reimbursement and cost-containment, with increased customer price sensitivity, including pricing pressure recently experienced in China.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- tariffs — estimated $200-350M net FY2026 impact (US 30%/China 10% base; up to US 145%/China 125%)high
Medtronic estimates a net tariff impact of $200-350 million in FY2026 from U.S., China and other tariffs; the low end assumes current U.S. 30% / China 10% rates persist, the high end assumes reversion to U.S. 145% / China 125% after the 90-day pause — with most recognized in the back half of the year.
“we estimate the net tariff impact to be $200 million to $350 million in fiscal year 2026, with the majority recognized in the consolidated statements of income in the second half of the fiscal year. The lower end of the range assumes that the current U.S. (30%) and China (10%) tariffs persist, while the higher end of the range assumes tariffs revert to higher rates (U.S. 145%, China 125%) after the 90-day pause.”
- healthcare reimbursement/coverage changes and cost-containment price sensitivity (incl. China)medium
Changes by healthcare-system administrators in coverage or reimbursement could significantly reduce reimbursement or deny coverage, affecting demand and the prices customers will pay; cost-containment and risk-sharing arrangements (and pricing pressure recently experienced in China) have increased customer price sensitivity.
“changes by administrators of these systems in coverage or reimbursement, could significantly reduce reimbursement or result in the denial of coverage, which could have an impact on the acceptance of and demand for our products and the prices that our customers are willing to pay for them.”
Sole-source dependency
- certain components, raw materials and services available only from sole suppliers; FDA requalification delayhigh
Certain components, raw materials and services Medtronic needs are obtained from sole suppliers; because of FDA and other regulators' stringent manufacturing requirements, it may not be able to quickly establish additional or replacement sources if supply is reduced or interrupted.
“for reasons of quality assurance, cost effectiveness, or availability, certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers... due to the stringent regulations and requirements of trade and regulatory agencies, including the U.S. FDA, regarding the manufacture of our products, we may not be able to quickly establish additional or replacem”
SEC filing →As of 2025
Geographic concentration
- largest manufacturing in US, Puerto Rico, Mexico, China, Ireland, Dominican Republic, Switzerland, France, Italylow
Medtronic's ~9.9M sq ft of manufacturing/research space is concentrated in its largest facilities located in the U.S., Puerto Rico, Mexico, China, Ireland, Dominican Republic, Switzerland, France and Italy — many serving multiple divisions.
“The Company's largest manufacturing facilities are located in the U.S., Puerto Rico, Mexico, China, Ireland, Dominican Republic, Switzerland, France, and Italy.”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“Significant Customers OTHER FACTORS IMPACTING OUR OPERATIONS Revenue from Abbott and Medtronic represented approximately 16% and 12%, respectively, of our consolidated revenue for fiscal 2024.”
Cited →“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch